Related Experiment Videos
Pediatric angiocardiography with iohexol
Insights
Iohexol, a nonionic contrast medium, demonstrated excellent safety and efficacy in pediatric angiocardiography for diagnosing congenital heart disease. The study found minimal adverse effects and high-quality imaging in young patients.
Area of Science:
- Pediatric Cardiology
- Radiology
- Medical Imaging
Background:
- Congenital heart disease necessitates advanced diagnostic imaging techniques.
- Nonionic contrast media are crucial for safe and effective angiocardiography.
Purpose of the Study:
- To evaluate the safety and efficacy of iohexol in pediatric angiocardiography.
- To assess adverse reactions and image quality in young patients with congenital heart disease.
Main Methods:
- 15 pediatric patients (6-82 months) with congenital heart disease underwent angiocardiography.
- Iohexol (350 mg iodine/ml) was administered at 2.46 ml/kg body weight.
- Vital signs, blood pressure, ECG, discomfort, and adverse reactions were monitored.
Main Results:
- 14 out of 15 patients experienced no adverse reactions.
- No significant changes in temperature or ECG were observed; blood pressure showed moderate changes.
- Excellent image quality was achieved, with minimal patient discomfort.
Conclusions:
- Iohexol is a safe and effective nonionic contrast medium for pediatric angiocardiography.
- It offers high-quality imaging with a favorable safety profile in infants and young children.
- Further research may explore long-term effects, though initial findings are highly positive.
Abstract:
A nonionic contrast medium (iohexol) was evaluated for safety and efficacy in pediatric angiocardiography in this study of 15 patients, age 6 to 82 months. Patients carried a preliminary diagnosis of congenital heart disease. Subjects were injected with iohexol, 350 mg iodine/ml of solution with an average volume of 2.46 ml/kg of body weight at a rate of 9 to 14.5 ml/sec. The parameters evaluated included vital signs, intravascular BP, ECG changes, discomfort, and adverse reactions. No adverse reactions were noted in 14 of 15 patients. No significant changes in axillary temperature of ECG were observed. Intravascular blood pressure showed only moderate changes. After 24 hours, creatine phosphokinase (CPK) plasma concentrations increased significantly. Serum electrolytes remained unchanged. Image quality was deemed excellent considering variations in injection site and flow condition of the heart. Iohexol caused remarkably little discomfort and no adverse effects.